The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...
A wall showing a Merck & Co. logo in Kenilworth, New Jersey This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback